Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-10
Target enrollment:
Participant gender:
Summary
This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with
platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with
tislelizumab after surgery in patients with stage III non-small cell lung cancer.